Anavex Life Sciences Corp. (AVXL)
After hours:
| Previous close | 5.66 |
| Open | 5.60 |
| Bid | 5.56 x 100 |
| Ask | 5.65 x 100 |
| Day's range | 5.47 - 5.75 |
| 52-week range | 3.25 - 10.45 |
| Volume | |
| Avg. volume | 922,135 |
| Market cap | 474.855M |
| Beta (5Y monthly) | 0.61 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.51 |
| Earnings date | 25 Nov 2024 - 29 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.47 |
Simply Wall St.Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near?
We feel now is a pretty good time to analyse Anavex Life Sciences Corp.'s ( NASDAQ:AVXL ) business as it appears the...
GlobeNewswireAnavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of
- Associated Press Finance
Anavex Life Sciences: Fiscal Q3 Earnings Snapshot
NEW YORK (AP) — Anavex Life Sciences Corp. AVXL) on Tuesday reported a loss of $12.2 million in its fiscal third quarter. On a per-share basis, the New York-based company said it had a loss of 14 cents.
